Government rules changed to ensure availability of GLP-1 RAs 5 June 2024 From this week, Government rules have been changed to ensure medicines like Ozempic and Trulicity are available for the people who need them most. These medicines are called glucagon-like peptide 1 receptor agonists or GLP-1 RAs. When the government began subsidising GLP-1 RAs they could only be available if you were being treated with other diabetes medicines (like metformin, insulin, etc) and the other medicines weren’t working to reduce your blood glucose, or you had a reaction. However, data shows that people were being prescribed GLP-1 RAs outside of these rules. In order to deal with this, the rules have been changed to: Increase access by only requiring one other medicine to have been tried (e.g. metformin), and Require doctors to get phone authorization before they can prescribe GLP-1 RAs to new users. If you’re already on Ozempic or another GLP-1 RA and it is funded through the government, these new rules shouldn’t affect you. We know that GLP-1 RAs are in short supply, and we don’t think these rules will have an immediate effect on your ability to get access to these medicines. More information is available from the PBS website.
News 23 July 2025 Ozempic supply returning to normal in Australia Diabetes Australia has welcomed confirmation that the supply of Ozempic (semaglutide) in Australia has stabilised, with prescribing and supply restrictions... Continue Reading
Media releases 18 July 2025 Youfoodz partners with Diabetes Australia to support Australians living with diabetes Youfoodz, a HelloFresh company, and one of Australia’s leading ready-made meal providers, has today confirmed a new national partnership with... Continue Reading
Media releases 17 July 2025 AI health app to supercharge living well with type 2 diabetes Australians living with or at risk of developing type 2 diabetes will, for the first time, have free access to... Continue Reading